All News

MYC Status Relevant to Risk Stratification in Newly Diagnosed Multiple Myeloma

October 29, 2020

In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.

High-Risk MCL Population Represents Unmet Need in Treatment Landscape

October 28, 2020

The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.

FoundationOne Liquid CDx Granted New and Expanded FDA Indications in Various Solid Tumors

October 28, 2020

The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.

Adjuvant Osimertinib Induces Promising CNS DFS in Early Stage EGFR-Mutant NSCLC

October 27, 2020

In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings for the ADAURA study, which explored the role of osimertinib as treatment of patients with early-stage EGFR-mutant non-small cell lung cancer following a complete tumor resection.

New and Updated Data in GI Cancer Trials Show Continued Benefit With Targeted and Immunotherapy Agents

October 26, 2020

Historically, in gastrointestinal malignancies, chemotherapy and radiation were utilized to improve outcomes for patients. Although these treatments were effective, disease recurrence was always imminent, demonstrating a need for novel therapies.